MAG-O3® MAG-EPA Concentrate
The concentrated EPA formula designed for better absorption.
- 525 mg EPA per capsule
- Only 15 mg DHA
- Patented monoglyceride form clinically studied in Quebec, Canada
- Up to ~3.5x more blood EPA vs ethyl esters (EE)
- Up to ~2x more blood EPA vs re-esterified triglycerides (rTG)
- Formulated to support the Omega-3 Index and AA:EPA ratio
- Source of EPA for the maintenance of good health
- Designed for a no fishy aftertaste experience
- IFOS Certified
- NPN: 80122883
- Available in 30 or 60 softgel formats.
-
GTIN: 990312010319 / 628942179594
Why a Concentrated EPA Formula?
EPA and DHA are two complementary omega-3 fatty acids, but they do not play the same role in the body.
EPA is particularly studied for its role in cellular signaling and the balance of inflammatory mediators.
DHA, on the other hand, is more concentrated in the membranes of the brain, eyes, and nervous system.
MAG-O3® MAG-EPA Concentrate was formulated to focus delivery on EPA, with a high dose and a monoglyceride form designed to optimize absorption.
How MAG-O3® Technology Works
A form designed for better absorption. Conventional fish oils must first be digested before EPA and DHA can be absorbed.
MAG-O3® delivers omega-3s in monoglyceride form, a pre-digested structure that is more easily absorbed by the intestine.
Cette technologie permet de livrer davantage d’EPA et de DHA aux cellules, à dose égale.
How MAG-O3® Technology Works
A form designed for better absorption. Conventional fish oils must first be digested before EPA and DHA can be absorbed.
MAG-O3® delivers omega-3s in monoglyceride form, a pre-digested structure that is more easily absorbed by the intestine.
This technology helps deliver more EPA and DHA to cells at the same dose.
La recherche derrière MAG-O3® Concentré de MAG-EPA
✔ Technologie canadienne brevetée
✔ Développée au Québec par Samuel Fortin, PhD
✔ Plus de 12 ans de recherche
✔ Études précliniques et cliniques publiées
✔ Recherche sur l’Indice Oméga-3 et le ratio AA:EPA
Absorption supérieure observée
Dans une étude clinique publiée, la forme monoglycéride MAG-O3® a livré jusqu’à :
- ~3.5x plus d’EPA que les esters éthyliques (EE)
- ~2x plus que les triglycérides reconstitués (rTG)
à dose égale.
Ratio AA:EPA amélioré en 12 semaines
Dans l’étude IO3-04, 2 g d’EPA MAG-O3® par jour pendant 12 semaines ont permis :
- une hausse de l’Indice Oméga-3 de 5,3 % à 9,4 %
- une diminution du ratio AA:EPA de 14,0 à 2,2
The Research Behind MAG-O3® MAG-EPA Concentrate
✔ Patented Canadian technology
✔ Developed in Quebec by Samuel Fortin, PhD
✔ More than 12 years of research
✔ Published preclinical and clinical studies
✔ Research on the Omega-3 Index and AA:EPA ratio
Superior absorption observed
In a published clinical study, the MAG-O3® monoglyceride form delivered up to:
- ~3.5x more EPA than ethyl esters (EE)
- ~2x more than re-esterified triglycerides (rTG)
at the same dose.
Improved AA:EPA ratio in 12 weeks
In the IO3-04 study, 2 g of MAG-O3® EPA daily for 12 weeks resulted in:
- an increase in Omega-3 Index from 5.3% to 9.4%
- a reduction in the AA:EPA ratio from 14.0 to 2.2
All MAG-O3® Products Are IFOS Certified
Our MAG-O3® monoglyceride omega-3 products undergo rigorous testing and have received IFOS 5-Star certification, the highest international standard for fish oil purity, freshness, and potency.
Programme Santé Cellulaire EB Supplements
Phase I — Réinitialiser (2 semaines)
- Fisétine+ Complexe Santé Cellulaire: Soutien inspiré de la recherche sur les composés sénolytiques.
Phase II — Protéger & Entretenir (8 à 12 semaines)
- Entretien Cellulaire + MAG-O3 au Quotidien et/ou MAG-EPA Concentré: Soutien du NAD+, de l’énergie cellulaire et de la santé des membranes.
Recommencer
Le programme est conçu pour être répété en cycles, avec un point de contrôle auprès d'un praticien de soins de santé au-delà de 12 semaines.
MAG-O3® MAG-EPA Concentré peut se prendre seul comme formule oméga-3 concentrée en EPA, ou être combiné à MAG-O3® Oméga-3 au Quotidien ou MAG-O3® Oméga-3 mini selon vos besoins en EPA et DHA. Il constitue également l’option ciblée en EPA de la Phase II du Programme Santé Cellulaire EB Supplements.
EB Supplements Cellular Health Program
Phase I | Regulation (2 weeks)
- Fisetin+ Cellular Health Complex: Support inspired by research on senolytic compounds.
Phase II | Protect & Maintain (8 to 12 weeks)
- Cellular Maintenance + MAG-O3® Daily Omega-3 or mini, with or without MAG-EPA Concentrate: Support for NAD+, cellular energy, and membrane health.
Repeat
The program is designed to be repeated in cycles, with follow-up from a healthcare practitioner beyond 12 weeks when needed.
MAG-O3® MAG-EPA Concentrate can be taken alone as a concentrated EPA omega-3 formula, or combined with MAG-O3® Daily Omega-3 or MAG-O3® Omega-3 mini depending on your EPA and DHA needs. It also serves as the targeted EPA option in Phase II of the EB Supplements Cellular Health Program.
FAQ
Have a question that isn’t answered here? Write us, we reply to every message.
Both are long-chain omega-3 fatty acids, but they play different roles in the body. EPA is the fatty acid most directly involved in cellular signaling and eicosanoid balance, the pathways researchers refer to when discussing inflammatory tone. DHA is primarily structural and is concentrated in the membranes of the brain, retina, and nervous system. Both matter. MAG-EPA focuses delivery on EPA, while MAG-O3® Daily Omega-3 provides a balanced EPA/DHA profile.
Standard omega-3s such as ethyl esters (EE) and triglycerides (TG) must first be broken down by bile and pancreatic lipase before absorption can occur. The MAG monoglyceride form is already “pre-digested”: one fatty acid attached to one glycerol molecule, ready for direct absorption. Published pharmacokinetic research associated the MAG form with approximately: 3x greater blood EPA response versus EE omega-3s 2x greater response versus re-esterified triglycerides (rTG) (Chevalier et al., 2021)
Both use the same patented MAG-O3® monoglyceride technology. MAG-O3® Daily Omega-3 provides a balanced EPA/DHA profile for broad daily support. MAG-EPA is EPA-focused (525 mg EPA · 15 mg DHA per softgel) and designed for users prioritizing: cellular signaling support inflammatory balance support recovery or improving a low EPA Omega-3 Index The two formulas can also be combined depending on your needs and practitioner guidance.
Yes. The two formulas can be combined when needed. Many users take MAG-O3® Daily Omega-3 as their balanced EPA/DHA foundation and add MAG-EPA when their priority shifts toward signaling support, recovery, or improving a low EPA Omega-3 Index. Discuss combinations with your healthcare practitioner to tailor EPA and DHA intake to your goals.
2 softgels daily = 1,050 mg EPA 4 softgels daily = 2,100 mg EPA Maximum adult dosage (6 softgels daily) = 3,150 mg EPA Adult dosage ranges from 2 to 6 softgels daily. For adolescents aged 14–18 years: 1 to 4 softgels daily.
Two factors matter: concentration and absorption. A standard 1,000 mg fish oil softgel typically contains about 180 mg EPA. To match two MAG-EPA softgels (1,050 mg EPA), you would need approximately six conventional capsules. On top of that, EE and TG forms face absorption limitations. MAG-EPA combines both high concentration and optimized molecular form to deliver more usable EPA with fewer capsules.
Omega-3 changes are biological, not stimulant-like. The Omega-3 Index and AA:EPA ratio evolve measurably over 8–12 weeks of consistent EPA supplementation (see IO3-04 study in the research section). Subjective changes such as recovery, end-of-day energy, or joint comfort vary between individuals and tend to emerge progressively over a full Phase II cycle.
Yes. Every batch is independently tested through the International Fish Oil Standards (IFOS) program. MAG-EPA carries the IFOS 5-Star rating, the program’s highest certification level, evaluating: heavy metals PCBs dioxins label potency and oxidation markers
Most users report little to no fish burps or fishy aftertaste with MAG-EPA, and the reason is largely mechanical. Conventional hydrophobic fish oils float on top of stomach fluids. During reflux, this oil layer rises first along with its characteristic odor. The MAG-O3® monoglyceride form is self-emulsifying, meaning it mixes with stomach fluids rather than floating on top. Freshness also matters. Each batch undergoes IFOS oxidation testing to help minimize rancidity, another common source of fishy aftertaste. Some sensitive individuals may still experience mild gastrointestinal effects, which are usually improved by taking the product with meals.
MAG-O3® fish oil is produced in Norway from small wild fish sourced from sustainable fisheries: anchovy sardine herring mackerel (Engraulidae, Clupeidae, and Scombridae families) Each batch is certified: Friend of the Sea for sustainability IFOS 5-Star for purity, freshness, and potency
MAG-EPA is a Phase II product. Phase I (Fisetin+, 2 weeks) focuses on reset. Phase II (Cellular Maintenance + either MAG-O3® Daily Omega-3 or MAG-EPA for 8–12 weeks) focuses on maintenance and rebuilding. Choose MAG-EPA when your Phase II objective is concentrated EPA support. The cycle can then be repeated, with healthcare practitioner guidance for programs extending beyond 12 weeks.